N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(4-pyridinylthio)phenyl)urea

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(4-pyridinylthio)phenyl)urea
• 英文别名: N-(5-trifluoromethyl-2-methoxyphenyl)-N'-(4-(4-pyridinylthio)phenyl)urea；n-(2-Methoxy-5-(trifluoromethyl)phenyl)-n'(4-(4-pyridinylthio)phenyl)urea；1-[2-methoxy-5-(trifluoromethyl)phenyl]-3-(4-pyridin-4-ylsulfanylphenyl)urea
• 化学式: C₂₀H₁₆F₃N₃O₂S
• 分子量: 419.427
• InChiKey: XSIGIAGUVJSXBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  88.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  、 2-甲氧基-5-三氟甲基苯胺 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(4-pyridinylthio)phenyl)urea
  参考文献：
  名称：

  INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

  摘要：

  公开号：

  EP1042305B1

文献信息

• Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
  申请人：Miller Scott

  公开号：US20080269265A1

  公开（公告）日：2008-10-30

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
  申请人：BAYER CORPORATION

  公开号：US20040102636A1

  公开（公告）日：2004-05-27

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的药物组合物。
• Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
  申请人：Bayer Corporation

  公开号：EP1449834A3

  公开（公告）日：2004-12-22

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
  申请人：Miller Scott

  公开号：US20090093526A1

  公开（公告）日：2009-04-09

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的制药组合物。
• Methods for promoting survival of transplanted tissues and cells
  申请人：Johnson & Johnson Vision Care, Inc.

  公开号：EP1676574A2

  公开（公告）日：2006-07-05

  Methods for enhancing the survival of a cell, tissue, or organ transplanted into a recipient comprising contacting the cell, tissue, or organ graft with an agent that decreases the rate of coagulation on the transplanted cell, tissue or organ are disclosed. The agent is one that acts by reducing the amount or activity of tissue factor (TF) on the donor tissue, such as a p38 MAPK inhibitor, a JNK inhibitor, a p38 MAPK/JNK dual inhibitor and a TF antagonist. Cells, tissues and organs treated with those agents are also disclosed.

  本发明公开了提高移植到受者体内的细胞、组织或器官存活率的方法，该方法包括使细胞、组织或器官移植体与一种能降低移植细胞、组织或器官凝血率的药剂接触。这种药剂通过减少供体组织上组织因子（TF）的数量或活性发挥作用，如 p38 MAPK 抑制剂、JNK 抑制剂、p38 MAPK/JNK 双抑制剂和 TF 拮抗剂。还公开了用这些制剂处理的细胞、组织和器官。